Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 10, 2026

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model
11:38

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Published on: July 2, 2016

APOBEC3G-Augmented Stem Cell Therapy to Modulate HIV Replication: A Computational Study.

Iraj Hosseini1, Feilim Mac Gabhann

  • 1Institute for Computational Medicine, Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland, USA. ihossei1@jhu.edu

Plos One
|June 1, 2013
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Generalized Minimal PBPK-PD Model of Bispecific Antibodies: Case Studies and Applications in Drug Development.

CPT: pharmacometrics & systems pharmacology·2025
Same author

A quantitative systems pharmacology model to inform clinical translation of dynamic PKPD relationships of engineered IL-15.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2025
Same author

Mechanistic computational modeling of sFLT1 secretion dynamics.

PLoS computational biology·2025
Same author

Impact of ligand binding on VEGFR1, VEGFR2, and NRP1 localization in human endothelial cells.

PLoS computational biology·2025
Same author

Effectorless Fc-fusion improves FLT3L drug-like properties for cancer immunotherapy combinations.

EBioMedicine·2025
Same author

Mechanistic computational modeling of sFLT1 secretion dynamics.

bioRxiv : the preprint server for biology·2025
Same journal

Analysis of strength degradation of coal and rock masses and stability of mined areas under long term immersion environment.

PloS one·2026
Same journal

Biogenic Silver-Selenium nanocomposite with anticancer activity and potent efficacy against vancomycin-resistant Staphylococcus aureus.

PloS one·2026
Same journal

Preparation and physicochemical characterization of a biodegradable chitosan/carboxymethyl cellulose hydrogel synthesized in NaOH/urea medium.

PloS one·2026
Same journal

Action-guilt, survivor-guilt, and depression in combat-related PTSD.

PloS one·2026
Same journal

Explainable machine learning for predicting activities of daily living at discharge in stroke patients: A retrospective study using SHAP interpretability.

PloS one·2026
Same journal

Deep learning based two-way feature depiction model for brain tumor detection.

PloS one·2026
See all related articles

Gene therapy using stem cells to boost APOBEC3G (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G) shows promise for inhibiting HIV replication. Overexpressing APOBEC3G in CD4+ T cells could be an effective HIV treatment strategy.

Area of Science:

  • Immunology
  • Virology
  • Biotechnology

Background:

  • The innate immune system employs APOBEC3G (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G) to restrict HIV infection by mutating viral DNA and blocking reverse transcription.
  • HIV protein Vif counteracts APOBEC3G's antiviral functions by preventing its encapsulation, yet APOBEC3G overexpression or Vif-APOBEC3G binding interference can inhibit HIV replication.
  • Clinical studies suggest a correlation between high APOBEC3G expression and better HIV patient outcomes, though results are conflicting.

Purpose of the Study:

  • To quantitatively assess the impact of APOBEC3G-overexpressing stem cell therapy on in vivo HIV replication using a mathematical model.
  • To explore the potential of genetically encoding APOBEC3G for therapeutic delivery via stem cells.
  • To simulate combination therapies involving APOBEC3G and other biological interventions for improved HIV treatment outcomes.

More Related Videos

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

Related Experiment Videos

Last Updated: May 10, 2026

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model
11:38

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Published on: July 2, 2016

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

Main Methods:

  • Development of a mathematical model to simulate HIV replication dynamics in vivo.
  • Modeling the therapeutic delivery of CD34+ stem cells genetically modified to overexpress APOBEC3G.
  • Simulation of combination therapies integrating APOBEC3G overexpression with other biological activities.

Main Results:

  • The mathematical model indicates that a high proportion of APOBEC3G-overexpressing CD4+ T cells can effectively suppress in vivo HIV replication.
  • The model provides a framework for quantitatively evaluating the efficacy of APOBEC3G-based stem cell therapy.
  • Simulations suggest potential for improved outcomes when APOBEC3G therapy is combined with other interventions.

Conclusions:

  • Stem cell therapy engineered for APOBEC3G overexpression presents a viable strategy for inhibiting HIV replication in vivo.
  • Genetic encoding of APOBEC3G offers an advantage for therapeutic applications compared to non-genetically encoded small molecules.
  • Further modeling of combination therapies can help optimize treatment protocols for HIV management.